Cervical Cancer in India

Cervical Cancer in India mind map
  Recent News
    Special Push in Budget 2024
    India's First Indigenous HPV Vaccine
      Name
        Cervavac
      Manufacturer
        Serum Institute of India
      Type
        Quadrivalent
      Cost
        ₹4,000 for two doses
        ₹2,000 per dose
  When
    Early Vaccination Optimal
      Age
        9 to 14 years
  Why
    Prevention of Cervical Cancer
  What
    Symptoms
      Early Stages
        Often Asymptomatic
      Advanced Stages
        Unusual Vaginal Bleeding
        Foul-smelling Discharge
        Pelvic Pain
    HPV Vaccines
      Types
        Cervarix
          Bivalent
          Protects Against
            HPV Types 16, 18
        Gardasil
          Quadrivalent
          Protects Against
            HPV Types 16, 18, 6, 11
          Cost
            ₹3,957 per dose
        Cervavac
          Quadrivalent
          Made in India
    Screening Methods
      Importance in Prevention
    Treatment Services
      Accessibility Issues
  Where
    Urban and Rural India
      Urban Trends
        Breast Cancer More Common
      Rural Trends
        High Incidence of Cervical Cancer
  Who
    Key Figures
      Dr. Priya SP Patil
        Consultant Obstetrician and Gynaecologist
      Dr. Vigyan Mishra
        Chief of Lab-Neuberg Diagnostics
      Dr. Niti Raizada
        Senior Director, Medical Oncology, Fortis Hospitals
  How
    Vaccination Programs
    Government Initiatives
      Budget Allocation
      Public Health Centre Distribution
  Significance
    Preventable and Curable Disease
    Potential for Cervical Cancer Elimination
    Reduction in Other HPV-related Cancers
  Challenges
    High Vaccine Costs
    Accessibility in Rural Areas
    Social and Economic Constraints
  Way Forward
    Achieve 90% Vaccination by 2030
    Increase Public Awareness
    Enhance Accessibility in Rural Areas

Cervical cancer in India is a critical health concern, currently receiving heightened attention due to the introduction of vaccination initiatives in the 2024 budget. The disease, once predominant among women, especially in rural areas, is now preventable and curable with early detection and vaccination. India has introduced its first indigenous HPV vaccine, Cervavac, developed by the Serum Institute of India. This quadrivalent vaccine is a proactive step towards reducing cervical cancer risk and is most effective when administered to young individuals between 9 to 14 years. Challenges remain in terms of vaccine accessibility and cost, particularly in rural areas. The government’s recent efforts aim to make the vaccine more accessible through public health centres, targeting a 90% vaccination rate by 2030. This approach not only addresses cervical cancer but also other HPV-related cancers, underscoring the significance of early intervention and widespread vaccination programs in India.

Related Posts

If you like this post, please share your feedback in the comments section below so that we will upload more posts like this.

Responses

🖍️ Highlight
HomeCoursesPlansAccount